Tag Archives: Intra-Cellular Therapies

Cowen & Co. Thinks Intra-Cellular Therapies’ Stock is Going to Recover

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), with a price target of $28. The company’s shares opened today at $10.98, close to its 52-week low

Cantor Fitzgerald Keeps a Buy Rating on Intra-Cellular Therapies (ITCI)

In a report released today, Charles Duncan from Cantor Fitzgerald reiterated a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), with a price target of $26. The company’s shares opened today at $13.94. Duncan said: “. We reiterate our

Cantor Fitzgerald Maintains a Buy Rating on Intra-Cellular Therapies (ITCI)

Cantor Fitzgerald analyst Charles Duncan maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report) today and set a price target of $26. The company’s shares opened today at $12.60. Duncan noted: “Core to our investment thesis is the

Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (NASDAQ: ITCI) and CymaBay Therapeutics (NASDAQ: CBAY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intra-Cellular Therapies (ITCI – Research Report) and CymaBay Therapeutics (CBAY – Research Report) with bullish sentiments. Intra-Cellular Therapies (ITCI) In a report

A Director at Intra-Cellular Therapies is Exercising Options

Today it was reported that a Director at Intra-Cellular Therapies (NASDAQ: ITCI), Richard A. Lerner, exercised options to buy 12,500 ITCI shares at $1.50 a share, for a total transaction value of $18.75K. The options were close to expired and

Intra-Cellular Therapies (ITCI) Gets a Buy Rating from Cantor Fitzgerald

In a report released today, Charles Duncan from Cantor Fitzgerald maintained a Buy rating on Intra-Cellular Therapies (NASDAQ: ITCI), with a price target of $32. The company’s shares closed yesterday at $20.75. Duncan wrote: “We are Overweight ITCI with a